



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Usgena

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB / EMA/VR/0000361872	Outcome: Q.II.f.1.b) Extension of the shelf life of the finished product - Q.II.f.1.b.1 As packaged for sale (supported by real time data, fully in line with the stability protocol) - Accepted	10/08/2026		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



Variation type II / EMA/VR/0000337104	Outcome: Q.II.d.1 Change in the specification attribute and/or acceptance criteria of the finished product - Q.II.d.1.e) Change outside of the specification acceptance criteria of the finished product - Accepted	28/05/2026			
Variation type IB / EMA/VR/0000342026	Outcome: This was an application for a group of variations. Q.II.b.4 Change in the batch size (including batch size ranges) of the finished product - Q.II.b.4.f) The scale for a biological finished product is increased/decreased without process change (e.g. duplication of line) - Accepted Q.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Q.II.b.3.a) Minor change in the manufacturing process - Accepted	08/05/2026			
Variation type IB / EMA/VR/0000338332	Outcome: Q.II.f.1.b) Extension of the shelf life of the finished product - Q.II.f.1.b.1 As packaged for sale (supported by real time data, fully in line with the stability protocol) - Accepted	31/03/2026		SmPC	

Variation type IA / EMA/VR/0000323837	Outcome: This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.a Tightening of in-process limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted	30/01/2026			
--	--	------------	--	--	--

	B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.b Addition of a new in-process test and limits - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting				
--	---	--	--	--	--

	material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in-process limits - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in-process limits - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted				
--	---	--	--	--	--